Figure 5
Anti-proliferative activity of CG200745 in cholangiocarcinoma cells in a xenograft model. (a,b) Tumour size was measured twice weekly and at the end of the experiment, mice were sacrificed and tumours were dissected. Tumour volume was decreased in SNU-1196 and SNU-1196/GR cells treated with CG200745. Average tumour volumes in SNU-1196-injected mice were 599.4 ± 205.1 and 340.6 ± 57.1 mm3 (P = 0.06) for the saline and CG200745 groups, respectively; in SNU-1196/GR-injected mice, they were 959.0 ± 73.80 and 398.8 ± 67.42 mm3 (P < 0.001) for the saline and CG200745 groups, respectively. Five mice each were used for the SNU-1196 saline and CG200745 groups and six and eight mice were used for the SNU-1196/GR saline and CG200745 groups, respectively. Error bars represent SEM. ***p < 0.001. (c) Average tumour weights in SNU-1196-injected mice were 0.469 ± 0.162 and 0.200 ± 0.024 g (P = 0.07) for the saline and CG200745 groups, respectively; in SNU-1196/GR-injected mice, they were 0.543 ± 0.055 and 0.217 ± 0.026 g (P < 0.001) for the saline and CG200745 groups, respectively. Error bars are ± SEM. ***p < 0.001. (d) Average body weights of SNU-1196-injected mice were 21.9 ± 0.90 and 19.9 ± 0.55 g for the saline and CG200745 groups, respectively; in SNU-1196/GR-injected mice, they were 22.717 ± 0.342 and 20.737 ± 0.545 g for the saline and CG200745 groups, respectively.
